[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) filed a Form 144 reporting a proposed sale of 676 shares of common stock held at Fidelity Brokerage Services. The filing states the shares were acquired on 08/15/2025 upon restricted stock vesting and were paid as compensation. The filer lists an approximate sale date of 08/19/2025 and an aggregate market value of $17,974.90, with 19,018,573 shares outstanding and the intended exchange listed as NASDAQ. The form indicates no securities sold by the filer in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Routine insider notice for a small, vested equity sale; unlikely to be material to NKTR's valuation.

The filing documents a proposed sale of 676 shares valued at $17,974.90 following restricted stock vesting on 08/15/2025, with an approximate sale date of 08/19/2025. This is a routine Form 144 disclosure required when insiders or affiliates plan to sell restricted or control stock. The size of the sale relative to the 19,018,573 shares outstanding is negligible and the filer reports no other sales in the prior three months. Based solely on the filing, there is no new financial information about company operations or performance.

Corporate Governance Expert

TL;DR: Compliance filing showing standard reporting of vested equity and planned disposition, with no governance red flags stated.

The notice indicates shares were acquired via restricted stock vesting and will be sold through Fidelity Brokerage Services on NASDAQ. The filer affirms lack of undisclosed material adverse information, and no prior sales in the last three months are reported. From a governance standpoint, the document meets disclosure requirements for planned insider sales; it does not disclose any departures, related-party transactions, or changes in control.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	676	17974.90	19018573	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			676	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does NKTR's Form 144 report on 08/15/2025 and 08/19/2025?

The filing reports acquisition of 676 common shares on 08/15/2025 via restricted stock vesting and an approximate intended sale date of 08/19/2025.

How many shares and what aggregate value are listed in the NKTR Form 144?

The Form 144 lists 676 shares with an aggregate market value of $17,974.90.

Through which broker and exchange will the NKTR shares be sold?

The filing names Fidelity Brokerage Services LLC as the broker and lists NASDAQ as the securities exchange.

Were any NKTR securities sold by the filer in the past three months according to the filing?

No. The Form 144 states Nothing to Report for securities sold during the past three months.

What was the nature of acquisition and payment for the NKTR shares?

The shares were acquired by Restricted Stock Vesting on 08/15/2025 and payment is described as Compensation.